Prospective Multi-Center Observational Study to Assess Effectiveness of Venclexta (Venetoclax) in Population of Relapse or Refractory Chronic Lymphocytic Leukemia Patients in Routine Clinical Practice in Russian Federation (FORTE)
Latest Information Update: 13 Oct 2022
At a glance
- Drugs Venetoclax (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Acronyms FORTE
- Sponsors AbbVie
Most Recent Events
- 06 Oct 2022 Status changed from active, no longer recruiting to completed.
- 13 May 2021 Planned End Date changed from 3 Dec 2022 to 30 Sep 2022.
- 13 May 2021 Planned primary completion date changed from 3 Dec 2022 to 30 Sep 2022.